NEXGEL, Inc., an innovative company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the consumer over-the-counter, Rx, medical device and cosmetic markets, announced the creation of a wholly owned subsidiary, NEXGEL Rx, to purpose their all-natural hydrogels as a drug and cell delivery system.
LANGHORNE, PA / ACCESSWIRE / October 15, 2020 / NEXGEL, Inc., an innovative company developing ultra-gentle, high-water content E-beam hydrogels with a focus on the consumer over-the-counter, Rx, medical device and cosmetic markets, today announced the creation of a wholly owned subsidiary, NEXGEL Rx, to purpose their all-natural hydrogels as a drug and cell delivery system.
Orthopedics and other types of musculoskeletal surgery and procedure-based medicine will serve as the first target specialty. The biodegradable hydrogels created by NEXGEL represent a unique mechanism for delivery of novel peri-operative additives, such as mesenchymal stem cells. The company believes that the proprietary hydrogel scaffold can complement all aspects of pre-operative, intra-operative, and post-operative care. “Our distinguished SAB continues to make progress and is reviewing multiple opportunities for us. We are fortunate to have them working toward building value for our new RX subsidiary.” commented Adam Levy, NEXGEL’s Chief Executive Officer.
About NEXGEL, INC.
NEXGEL has been a leading provider of ultra-gentle, high-water content hydrogels to leading medical companies around the world. Based in Langhorne, Pennsylvania, we’ve been developing and manufacturing electron-beam cross-linked hydrogels for over 23 years. In that time, our team has formulated over 200 different combinations to bring some of the best over-the-counter, cosmetic, and natural ingredients to the skin in a gentle patch that can be worn for long periods of time with little to no irritation. NEXGEL, Your Skin Friendly Patch Co.
Forward Looking Statements
This press release contains certain forward-looking statements, including those relating to the Company’s product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange.
For more information, please contact:
William Odenthal
Director of Investment Banking
Alere Financial Partners
A Division of Cova Capital Partners,LLC
www.covacp.com
917-747-4762-CELL
wodenthal@alerefinancial.com
SOURCE: NEXGEL, Inc.
View source version on accesswire.com:
https://www.accesswire.com/610721/NEXGEL-INC-Announces-the-Creation-of-NEXGEL-Rx
